-

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Integra LifeSciences Holdings Corporation (IART)

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming November 13, 2023 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Integra LifeSciences Holdings Corporation (“Integra” or the “Company”) (NASDAQ: IART) common stock between March 11, 2019 and May 22, 2023, inclusive (the “Class Period”).

Investors suffering losses on their Integra investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.

On April 26, 2023, Integra announced that it had paused production at its Boston Facility and disclosed declining operation margins for the quarter and flat revenue growth projections, which the Company attributed to the manufacturing pause. On this news, Integra’s stock price fell $4.64, or 7.9%, to close at $54.20 per share on April 26, 2023, thereby injuring investors.

Then, on May 23, 2023, Integra disclosed that it had initiated a recall of its SurgiMed, PriMatrix, Revize, and TissueMend products manufactured at its Boston facility as far back as March 1, 2018. The Company attributed the recall to a finding that products may have been distributed with higher levels of endotoxins than permitted by the product specifications. As a result, the Company expects to write off approximately $22 million in inventory. On this news, Integra’s stock price fell $10.24, or 20.2%, to close at $40.48 per share on May 23, 2023, thereby injuring investors further.

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Integra had failed to take sufficient measures to remediate the violations identified by the FDA in the 2018 Form 483, 2019 Warning Letter, and the 2021 Form 483; (2) As a result of those deficiencies, since March 2018, all products manufactured in the Boston Facility had the potential for higher-than-permitted levels of endotoxin and would need to be recalled; (3) The Company was not making progress towards obtaining its PMA indication for SurgiMend, in part, because the manufacturing site that would produce the PMA product, the Boston Facility, was in continued violation of the FDA standards that Integra failed to rectify years after the initial notice of the violations and as a result the facility had to be shutdown to correct those ongoing deficiencies; and (4) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Integra common stock during the Class Period, you may move the Court no later than November 13, 2023 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

Law Offices of Howard G. Smith

NASDAQ:IART

Release Versions

Contacts

Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com

More News From Law Offices of Howard G. Smith

Deadline Alert: Portillo's Inc. Stockholders Face January 11, 2027 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Portillo's Inc. ("Portillo's" or the "Company") (NASDAQ: PTLO) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by January 11, 2027. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from September 19, 2023 through May 4, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Wassel v. Portillo's Inc. et...

Deadline Alert: Nuscale Power Corporation Stockholders Face January 11, 2027 Lead Plaintiff Deadline in Securities Fraud Class Action, The Law Offices of Howard G. Smith Highlights

BENSALEM, Pa.--(BUSINESS WIRE)--Nuscale Power Corporation ("Nuscale" or the "Company") (NYSE: SMR) investors who wish to serve as lead plaintiff in a pending securities fraud class action lawsuit must move the Court by January 11, 2027. The suit was filed on behalf of investors who purchased or otherwise acquired the Company's securities from February 27, 2026 through September 10, 2026, inclusive. The Law Offices of Howard G. Smith today highlighted the deadline in the case, Chiu-Yueh Chang v....

Securities Fraud Class Action Lawsuit Pending Against Fervo Energy Company: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

BENSALEM, Pa.--(BUSINESS WIRE)--Fervo Energy Company ("Fervo" or the "Company") (NASDAQ: FRVO) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired Class A common stock pursuant and/or traceable to the registration statement and prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 13, 2026 initial public offering (“IPO” or the “Offering”). Plaintiff pursues claims under Section 1...
Back to Newsroom